Dlangalala T, Musekiwa A, Mashamba-Thompson T
PLoS One. 2024; 19(7):e0307149.
PMID: 39024321
PMC: 11257344.
DOI: 10.1371/journal.pone.0307149.
Ahsberg J, Tersbol B, Puplampu P, Kwashie A, Commey J, Adusi-Poku Y
Front Public Health. 2024; 11:1271763.
PMID: 38249371
PMC: 10797072.
DOI: 10.3389/fpubh.2023.1271763.
Esmail A, Pooran A, Sabur N, Fadul M, Brar M, Oelofse S
J Clin Microbiol. 2020; 58(10).
PMID: 32727831
PMC: 7512177.
DOI: 10.1128/JCM.01032-20.
Pooran A, Theron G, Zijenah L, Chanda D, Clowes P, Mwenge L
Lancet Glob Health. 2019; 7(6):e798-e807.
PMID: 31097281
PMC: 7197817.
DOI: 10.1016/S2214-109X(19)30164-0.
Bassett I, Forman L, Govere S, Thulare H, Frank S, Mhlongo B
BMC Infect Dis. 2019; 19(1):110.
PMID: 30717693
PMC: 6360783.
DOI: 10.1186/s12879-019-3738-4.
Xpert MTB/RIF associated with improved treatment initiation among patients with smear-negative tuberculosis.
Zawedde-Muyanja S, Manabe Y, Sewankambo N, Nakiyingi L, Nakanjako D
Int J Tuberc Lung Dis. 2019; 22(12):1475-1480.
PMID: 30606320
PMC: 6306042.
DOI: 10.5588/ijtld.17.0460.
Rolling Out Xpert MTB/RIF for TB Detection in HIV-Infected Populations:An Opportunity for Systems Strengthening.
Pathmanathan I, Date A, Coggin W, Nkengasong J, Piatek A, Alexander H
Afr J Lab Med. 2017; 6(2).
PMID: 28785533
PMC: 5523912.
DOI: 10.4102/ajlm.v6i2.460.
Microbiologically Confirmed Tuberculosis: Factors Associated with Pre-Treatment Loss to Follow-Up, and Time to Treatment Initiation.
Mwansa-Kambafwile J, Maitshotlo B, Black A
PLoS One. 2017; 12(1):e0168659.
PMID: 28068347
PMC: 5222612.
DOI: 10.1371/journal.pone.0168659.
The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF.
Hanrahan C, Clouse K, Bassett J, Mutunga L, Selibas K, Stevens W
Int J Tuberc Lung Dis. 2015; 19(7):811-6.
PMID: 26056107
PMC: 4869324.
DOI: 10.5588/ijtld.15.0013.
Implementation Research to Inform the Use of Xpert MTB/RIF in Primary Health Care Facilities in High TB and HIV Settings in Resource Constrained Settings.
Muyoyeta M, Moyo M, Kasese N, Ndhlovu M, Milimo D, Mwanza W
PLoS One. 2015; 10(6):e0126376.
PMID: 26030301
PMC: 4451006.
DOI: 10.1371/journal.pone.0126376.
Diagnostic delays and clinical decision making with centralized Xpert MTB/RIF testing in Durban, South Africa.
Cohen G, Drain P, Noubary F, Cloete C, Bassett I
J Acquir Immune Defic Syndr. 2014; 67(3):e88-93.
PMID: 25314255
PMC: 4197409.
DOI: 10.1097/QAI.0000000000000309.
Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling.
Dowdy D, Houben R, Cohen T, Pai M, Cobelens F, Vassall A
Int J Tuberc Lung Dis. 2014; 18(9):1012-8.
PMID: 25189546
PMC: 4436823.
DOI: 10.5588/ijtld.13.0851.
Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa.
Dlamini-Mvelase N, Werner L, Phili R, Cele L, Mlisana K
BMC Infect Dis. 2014; 14:442.
PMID: 25129689
PMC: 4141089.
DOI: 10.1186/1471-2334-14-442.
Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in europe.
Tebruegge M, Ritz N, Koetz K, Noguera-Julian A, Seddon J, Welch S
PLoS One. 2014; 9(6):e99129.
PMID: 24922084
PMC: 4055680.
DOI: 10.1371/journal.pone.0099129.
A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis.
Dowdy D, Andrews J, Dodd P, Gilman R
Elife. 2014; 3.
PMID: 24898755
PMC: 4082287.
DOI: 10.7554/eLife.02565.
Serological diagnostic assays for HIV-associated tuberculosis in sub-Saharan Africa?.
Lawn S
Clin Vaccine Immunol. 2014; 21(6):787-90.
PMID: 24739979
PMC: 4054249.
DOI: 10.1128/CVI.00201-14.
HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays.
Lawn S, Kerkhoff A, Vogt M, Wood R
BMC Med. 2013; 11:231.
PMID: 24168211
PMC: 4231603.
DOI: 10.1186/1741-7015-11-231.
Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening.
Fenner L, Ballif M, Graber C, Nhandu V, Dusingize J, Cortes C
PLoS One. 2013; 8(10):e77697.
PMID: 24147059
PMC: 3798412.
DOI: 10.1371/journal.pone.0077697.
Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies.
Lawn S, Dheda K, Kerkhoff A, Peter J, Dorman S, Boehme C
BMC Infect Dis. 2013; 13:407.
PMID: 24004840
PMC: 3846798.
DOI: 10.1186/1471-2334-13-407.
Population-level impact of same-day microscopy and Xpert MTB/RIF for tuberculosis diagnosis in Africa.
Dowdy D, Davis J, den Boon S, Walter N, Katamba A, Cattamanchi A
PLoS One. 2013; 8(8):e70485.
PMID: 23950942
PMC: 3741313.
DOI: 10.1371/journal.pone.0070485.
